Founded in the Asia-Pacific and driven by scientific expertise and operational excellence, George Clinical’s mission is to improve the health of millions of people worldwide through clinical research supported by global service delivery, world-class scientific leadership and therapeutic specialties.
Click here to see our expertise by therapeutic area
George Clinical is a leading contract research organization (CRO), headquartered in Sydney, Australia, with approximately 350 people providing the full range of clinical trial services to pharmaceutical, medical device and diagnostic customers, for all trial phases, registration and post-marketing trials. George Clinical combines scientific and clinical leadership with expert trial delivery to create distinctive world-class solutions.
George Clinical’s parent organization, The George Institute for Global Health, is a leader in chronic disease research with a global network of experts with whom George Clinical engages. Together, this partnership enlists operationally-supported, internationally-recognized scientific leadership and an extensive series of investigator networks, which allows George Clinical to provide customizable, clinical trial excellence from trial design through all aspects of delivery.
As clinical trial costs and complexities escalate, our multi-disciplined experts provide customers with innovative solutions to access patient populations and reduce sponsor R&D costs, ensuring that their clinical trials have an impact for clinicians and patients, while maintaining the highest scientific integrity.
The George Institute for Global Health
In 1999, The George Institute for Global Health was first founded in Australia with the aim of reducing the escalating burden of non-communicable diseases and injury around the world. Today it has grown to span more than 50 countries with 600 people across all global centers. The institute has raised almost $750 million for global health research to target the leading causes of death and disability worldwide. It is now ranked in the leading ten research institutions in the world for scientific impact. Click here to learn more.
George Clinical and EPS International Strategic Partnership
George Clinical and EPS International (EPSI) deliver service offerings in Asia-Pacific, the world’s most populous region, as well as worldwide for respective clients.
With this partnership, EPSI delivers clinical trial services for George Clinical clients in Japan; George Clinical provides clinical trial services for EPSI and its Japanese customers across Asia, the United States and Europe. In Asia, both companies provide a seamless operating capability for clinical trials across the Asia-Pacific region with the exception of China where both EPSI and George Clinical maintain an independent operating presence.
Since its establishment in 1991 as a pioneering CRO, EPS Group has been a healthcare solution provider to pharmaceutical companies, medical device manufacturers, hospitals and clinics, and academia with various solutions including development, marketing, sales, and consultation covering Asia centered in China. New value is currently being created in big data and AI, regenerative medicine, and more. The strength of EPSI lies in the fact that it has the greatest presence in Japan. In Asia, the company has multiple overseas offices and has focused particularly on solidifying its sites in the respective Asian countries, providing clinical development support services as well as SMO services. Learn more about EPSI here and here.